Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
29 January 2026 - Allergy Therapeutics plc (AIM:AGY), the fully commercial biotechnology company specialising in allergy immunotherapies, announces that all resolutions proposed at the 2026 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.
Resolutions 1 to 10 (inclusive), were proposed as ordinary resolutions and resolutions 11 to 13 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.
|
Resolution |
For: |
% |
Against: |
% |
Total Votes Cast |
% of ISC |
Withheld |
|
1. Approval of 2025 Accounts |
5,820,380,278 |
99.99% |
755,751 |
0.01% |
5,821,136,029 |
94.78% |
56,047 |
|
2. Approval of Directors' Remuneration Report |
5,820,138,203 |
99.99% |
836,062 |
0.01% |
5,820,974,265 |
94.78% |
217,811 |
|
3. To elect Helge Weiner-Trapness as a Director |
5,818,973,760 |
99.99% |
141,507 |
0.01% |
5,819,115,267 |
94.75% |
2,076,809 |
|
4. To elect Lawrence Allen Wang as a Director |
5,818,962,852 |
99.99% |
130,779 |
0.01% |
5,819,093,631 |
94.75% |
2,098,445 |
|
5. To re-elect Tunde Otulana as a Director |
5,818,680,380 |
99.99% |
418,353 |
0.01% |
5,819,098,733 |
94.75% |
2,093,343 |
|
6. To re-elect Cheryl MacDiarmid as a Director |
5,818,939,949 |
99.99% |
157,006 |
0.01% |
5,819,096,955 |
94.75% |
2,095,121 |
|
7. To re-elect Peter Jensen O.B.E. as a Director |
5,804,855,547 |
99.76% |
14,246,551 |
0.24% |
5,819,102,098 |
94.75% |
2,089,978 |
|
8. To re-appoint BDO LLP as auditors of the Company |
5,818,732,937 |
99.99% |
126,888 |
0.01% |
5,818,859,825 |
94.75% |
2,332,251 |
|
9. To authorise the Directors to agree the auditors' remuneration |
5,820,969,519 |
99.99% |
134,889 |
0.01% |
5,821,104,408 |
94.78% |
87,668 |
|
10. Authority to allot shares |
5,820,919,431 |
99.99% |
179,941 |
0.01% |
5,821,099,372 |
94.78% |
92,704 |
|
11. Special Resolution: Subject to the passing of Resolution 10, to authorise the Directors to allot equity securities |
5,817,602,998 |
99.94% |
3,509,576 |
0.06% |
5,821,112,574 |
94.78% |
79,502 |
|
12. Special Resolution: Subject to the passing of Resolution 10, to authorise the Directors, in addition to any authority granted under Resolution 11, to allot equity securities |
5,817,696,087 |
99.94% |
3,419,851 |
0.06% |
5,821,115,938 |
94.78% |
76,138 |
|
13. Special Resolution: To amend the Articles of Association |
5,818,896,008 |
99.99% |
198,676 |
0.01% |
5,819,094,684 |
94.75% |
2,097,392 |
- ENDS -
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus Fricker
Nigel Birks - Life Science Specialist Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries and branches in nine major European countries and via distribution agreements in an additional four countries. For more information, please see www.allergytherapeutics.com.